Tests have shown that the biosensors can detect a wide range of analytes (substances being measured), including biomarkers present
in prostate and ovarian cancer, stroke,
multiple sclerosis, heart disease and fungal infections. The team also believes that the biosensors are versatile enough to test for diseases such as tuberculosis and HIV.
The technology was developed through a European collaboration of researchers and commercial partners in a 2.7 million Euro project called ELISHA.